[go: up one dir, main page]

HK1205740A1 - Pyrrolotriazinone derivatives - Google Patents

Pyrrolotriazinone derivatives

Info

Publication number
HK1205740A1
HK1205740A1 HK15106267.6A HK15106267A HK1205740A1 HK 1205740 A1 HK1205740 A1 HK 1205740A1 HK 15106267 A HK15106267 A HK 15106267A HK 1205740 A1 HK1205740 A1 HK 1205740A1
Authority
HK
Hong Kong
Prior art keywords
pyrrolotriazinone derivatives
pyrrolotriazinone
derivatives
Prior art date
Application number
HK15106267.6A
Other languages
English (en)
Chinese (zh)
Inventor
Dieter Dorsch
Hans-Peter Buchstaller
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of HK1205740A1 publication Critical patent/HK1205740A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
HK15106267.6A 2012-05-04 2015-07-02 Pyrrolotriazinone derivatives HK1205740A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12003445 2012-05-04
PCT/EP2013/001026 WO2013164061A1 (en) 2012-05-04 2013-04-06 Pyrrolotriazinone derivatives

Publications (1)

Publication Number Publication Date
HK1205740A1 true HK1205740A1 (en) 2015-12-24

Family

ID=48050660

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15106267.6A HK1205740A1 (en) 2012-05-04 2015-07-02 Pyrrolotriazinone derivatives

Country Status (22)

Country Link
US (1) US9174995B2 (xx)
EP (1) EP2844659B1 (xx)
JP (1) JP6097820B2 (xx)
KR (1) KR20150006873A (xx)
CN (1) CN104271580B (xx)
AR (1) AR090896A1 (xx)
AU (1) AU2013257018B2 (xx)
CA (1) CA2872334C (xx)
EA (1) EA027628B1 (xx)
ES (1) ES2587939T3 (xx)
HK (1) HK1205740A1 (xx)
HR (1) HRP20161033T1 (xx)
HU (1) HUE028325T2 (xx)
IL (1) IL235414A (xx)
MX (1) MX357502B (xx)
PL (1) PL2844659T3 (xx)
PT (1) PT2844659T (xx)
RS (1) RS55062B1 (xx)
SG (1) SG11201406997WA (xx)
SI (1) SI2844659T1 (xx)
WO (1) WO2013164061A1 (xx)
ZA (1) ZA201408876B (xx)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9193689B2 (en) 2012-03-07 2015-11-24 Institute Of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
CN105722835B (zh) 2013-09-11 2018-07-31 癌症研究协会:皇家癌症医院 3-芳基-5-取代的-异喹啉-1-酮化合物及它们的疗法应用
HUE037606T2 (hu) * 2013-12-23 2018-09-28 Merck Patent Gmbh Imidazopirazinon-származékok
UY36060A (es) 2014-04-02 2015-10-30 Bayer Pharma AG Compuestos de azol sustituidos con amida
US9856262B2 (en) * 2014-04-10 2018-01-02 Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. Analogues of 4H-pyrazolo[1,5-a] benzimidazole compound as PARP inhibitors
KR20160007347A (ko) * 2014-07-11 2016-01-20 에스티팜 주식회사 신규한 이미다조트리아지논 또는 이미다조피라지논 유도체, 및 이들의 용도
KR101775356B1 (ko) * 2015-07-06 2017-09-06 재단법인 아산사회복지재단 Parp 및 탄키라제 동시 저해제에 대한 감수성 결정 방법
CA3038280A1 (en) * 2015-09-30 2017-04-06 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. - Generalverwaltung Heteroaryl derivatives as sepiapterin reductase inhibitors
WO2017055313A1 (en) 2015-10-01 2017-04-06 Bayer Pharma Aktiengesellschaft Amido-substituted azole compounds
WO2017055316A1 (en) 2015-10-01 2017-04-06 Bayer Pharma Aktiengesellschaft Amido-substituted azole compounds
EP3377495B1 (en) 2015-11-16 2022-03-16 Topadur Pharma AG 2-phenyl-3,4-dihydropyrrolo[2,1-f] [1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
WO2018078009A1 (en) 2016-10-29 2018-05-03 Bayer Pharma Aktiengesellschaft Amido-substituted cyclohexane derivatives
WO2018078005A1 (en) 2016-10-29 2018-05-03 Bayer Pharma Aktiengesellschaft Amido-substituted azaspiro derivatives as tankyrase inhibitors
WO2018087126A1 (en) 2016-11-09 2018-05-17 Bayer Pharma Aktiengesellschaft Amido-substituted cyclohexane derivatives as inhibitors of tankyrase
CN109180702B (zh) * 2018-10-29 2021-11-30 四川大学 一种噻吩并嘧啶酮化合物及其用途
CN111961058B (zh) * 2020-08-03 2022-12-16 天津全和诚科技有限责任公司 4-氨基-吡咯并三嗪衍生物及其制备方法和用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
ATE237596T1 (de) 1996-02-13 2003-05-15 Astrazeneca Ab Chinazolinderivate und deren verwendung als vegf hemmer
PT885198E (pt) 1996-03-05 2002-06-28 Astrazeneca Ab Derivados de 4-anilinoquinazolina
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
AU2001258628A1 (en) 2000-05-31 2001-12-11 Astrazeneca Ab Indole derivatives with vascular damaging activity
RU2003103603A (ru) 2000-07-07 2004-08-20 Энджиоджен Фармасьютикалз Лимитед (Gb) Производные колхинола в качестве ингибиторов ангиогенеза
CN1255391C (zh) 2000-07-07 2006-05-10 安吉奥金尼药品有限公司 作为血管破坏剂的colchinol衍生物
JP2006521398A (ja) 2003-03-28 2006-09-21 サイオス・インコーポレーテツド TGFβの二−環式ピリミジン阻害剤
CN100594903C (zh) 2004-09-30 2010-03-24 泰博特克药品有限公司 Hcv抑制性双环嘧啶
WO2008092861A1 (en) 2007-01-30 2008-08-07 Janssen Pharmaceutica N.V. Bicyclic derivatives as ep4 agonists
CA2678248C (en) 2007-03-08 2016-06-28 Janssen Pharmaceutica Nv Quinolinone derivatives as parp and tank inhibitors
EP2134716A1 (en) * 2007-04-18 2009-12-23 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors

Also Published As

Publication number Publication date
CA2872334C (en) 2020-06-30
ZA201408876B (en) 2017-06-28
AU2013257018B2 (en) 2017-02-16
CN104271580B (zh) 2017-02-22
SG11201406997WA (en) 2014-11-27
CA2872334A1 (en) 2013-11-07
EP2844659B1 (en) 2016-05-25
IL235414A (en) 2017-11-30
JP6097820B2 (ja) 2017-03-15
HRP20161033T1 (hr) 2016-10-21
RS55062B1 (sr) 2016-12-30
CN104271580A (zh) 2015-01-07
EA027628B1 (ru) 2017-08-31
MX2014013090A (es) 2014-12-08
US20150133453A1 (en) 2015-05-14
JP2015515961A (ja) 2015-06-04
AU2013257018A1 (en) 2014-12-18
EP2844659A1 (en) 2015-03-11
SI2844659T1 (sl) 2016-10-28
PL2844659T3 (pl) 2016-11-30
HUE028325T2 (en) 2016-12-28
ES2587939T3 (es) 2016-10-27
AR090896A1 (es) 2014-12-17
WO2013164061A8 (en) 2014-11-06
EA201401212A1 (ru) 2015-08-31
KR20150006873A (ko) 2015-01-19
WO2013164061A1 (en) 2013-11-07
PT2844659T (pt) 2016-08-31
US9174995B2 (en) 2015-11-03
MX357502B (es) 2018-07-12

Similar Documents

Publication Publication Date Title
HUS2200040I1 (hu) Benzimidazol-prolin származékok
DK3327112T3 (en) Agse-deficient stamme
DK2830816T3 (en) Hidtil ukendt coatingkoncept
HK1205740A1 (en) Pyrrolotriazinone derivatives
HK1205508A1 (en) New bicyclicpyridine derivatives
HK1207375A1 (en) Piperidinylpyrazolopyridine derivative
IL236295A (en) The history of indanesulfamide
ZA201502175B (en) Oxazolidin-2-one-pyrimidine derivatives
LT2838883T (lt) Nauji feniltetrahidroizochinolino dariniai
EP2812698A4 (en) TIME RESOLVED FREIGHT AND DOUBLE ACCEPTOR
HK1200824A1 (en) Substituted phenylazole derivative
EP2873660A4 (en) INDOLCARBOXAMIDDERIVAT
SG11201404325VA (en) Pyrimidooxazocine derivatives as mtor - inhibitors
HK1204621A1 (en) 4-alkanoylamino-3-pyrazolone derivative 4--3-
EP2834250A4 (de) Lithiumsilikate
AU345893S (en) Treehouse
GB201202887D0 (en) TV-audio

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20210402